They have disclosed they are developing iMSCs (iPSC-derived mesenchymal stem cells) as well.
Another program that is about to enter the clinic is NEUK203-13. NEUK203-13 represents an iterative upgrade of the first-generation product NEUK200-13. It is an anti-DLL3 CAR-iNK cell product. In addition to the CAR, an IL-15RF fusion gene is inserted into the CD38 locus, TIM-3 is knocked out, and a cleavage-resistant CD16 receptor has been inserted as well.
The phase one trial will test two dose levels in patients with advanced SCLC who have progressed after prior platinum-based chemo or late stage neuroendocrine tumours. After lymphodepletion, NEUK203-13 is administered via an IV infusion on days 1/4/7 and IL-2 is given on days 1/4/7/10.
Market Data 
Markets 
AI
